Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab

NCT01150643 | Completed

• 2 other identifiers: CDR0000675681ECOG-E4402T1
• Study Type: observational
• Target: 559
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Studying the effects of rituximab in blood and tumor tissue samples from patients with cancer in the laboratory may help doctors learn more about the effects of rituximab on cancer cells. It may also help doctors identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in samples from patients with follicular lymphoma treated with rituximab.

Conditions

Lymphoma

Keywords

stage III grade 1 follicular lymphoma; stage III grade 2 follicular lymphoma; stage IV grade 1 follicular lymphoma; stage IV grade 2 follicular lymphoma

Outcome Measures

Primary Outcomes (1)

• Correlation between FcγR polymorphisms and rituximab response, response duration, and time to resistance

  1 month

Interventions

gene expression analysis GENETIC

microarray analysis GENETIC

polymerase chain reaction GENETIC

polymorphism analysis GENETIC

immunohistochemistry staining method OTHER

laboratory biomarker analysis OTHER

Eligibility Criteria

• Age: 18 Years - 120 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Samples from patients enrolled on E4402 from whom samples were submitted for research

DISEASE CHARACTERISTICS: * Diagnosed with follicular lymphoma * Treated on ECOG-E4402 comprising 1 of 2 different rituximab-dose strategies * Banked peripheral blood mononuclear cells (PBMCs) and formalin-fixed paraffin-embedded (FFPE) tumor samples available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Eastern Cooperative Oncology Group: lead
• National Cancer Institute (NCI): collaborator

MeSH Terms

Conditions

Lymphoma; Lymphoma, Follicular

Interventions

Gene Expression Profiling; Microarray Analysis; Polymerase Chain Reaction; Amplified Fragment Length Polymorphism Analysis; Immunohistochemistry

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, Non-Hodgkin

Intervention Hierarchy (Ancestors)

Genetic Techniques; Investigative Techniques; Microchip Analytical Procedures; Nucleic Acid Amplification Techniques; DNA Fingerprinting; Histocytochemistry; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Histological Techniques; Immunologic Techniques

Study Officials

• Brad S. Kahl, MD

  University of Wisconsin, Madison

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 24, 2010
• First Posted: June 25, 2010
• Study Start: December 6, 2010
• Primary Completion: January 6, 2011
• Study Completion: January 6, 2011
• Last Updated: May 17, 2017

Record last verified: 2017-05